Blueprint
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 20 February 2018
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
 
GlaxoSmithKline plc (the 'Company')
Shares sold to meet tax liabilities
 
Following the vesting of awards granted in 2015 under the GlaxoSmithKline 2009 Performance Share Plan on 15 February 2018 and as notified on 16 February 2018, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
65,247
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing and Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
33,446
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
16,216
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$37.4803
14,389
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
26,605
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
35,473
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
SVP, Communications & Government Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
20,524
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$37.4803
31,635
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
73,783
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
 
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.0726
4,544
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 20, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc